Plaque psoriasis Trials in Louisville, United States
Conditions / Plaque psoriasis / Louisville, United States
Plaque psoriasis has been the subject of sustained clinical investigation across multiple research sites.
44 total trials for this combination
Showing top 10 of 44 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06846541 | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03573323 | A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis | COMPLETED | PHASE4 |
| NCT00570986 | A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis | COMPLETED | PHASE3 |
| NCT01708629 | Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects | TERMINATED | PHASE3 |
| NCT06550076 | A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02513550 | A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis | COMPLETED | PHASE3 |
| NCT02826603 | Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis | COMPLETED | PHASE3 |
| NCT06143878 | A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT06108544 | A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period | COMPLETED | PHASE3 |
| NCT06588738 | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 | ACTIVE_NOT_RECRUITING | PHASE3 |